{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T21:37:56Z","timestamp":1774129076268,"version":"3.50.1"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"29","license":[{"start":{"date-parts":[[2022,7,22]],"date-time":"2022-07-22T00:00:00Z","timestamp":1658448000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:p>Although the antitumor effects of antihypertensive drugs for patients with advanced pancreatic cancer (APC) have been investigated, their efficacy remains unclear. Previous studies suggest that hypertensive (HT) patients with APC are significantly older than non-HT patients with APC, and that other major baseline differences in patient characteristics which may affect prognosis exist between HT and non-HT patients. It is also possible that antihypertensive drugs lack antitumor activity. Therefore, we herein retrospectively investigated the baseline differences between HT and non-HT patients with APC. From January 2015 to April 2020, 56 patients with APC received nab-paclitaxel plus gemcitabine as first-line chemotherapy at Higashiosaka City Medical Center (Higashiosaka, Japan). Of these 56 patients, 30 were diagnosed with hypertension (HT group); the remaining 26 did not have hypertension (non-HT group). Differences between the two groups were compared and prognostic factors were evaluated. Patients in the HT group had significantly less sarcopenia, a significantly larger body mass index, were significantly older, and significantly more likely to have a regular doctor and primary site in the body and tail of the pancreas than those in the non-HT group. Although no significant difference was found in the treatment response, patients in the HT group were significantly more likely to move to second-line chemotherapy than those in the non-HT group. Survival curves showed that median overall survival (OS) in the HT group was significantly longer (10.5 months) than in the non-HT group (6.8 months, <jats:italic toggle=\"yes\">P<\/jats:italic> = .04). Multivariate analysis did not identify the use of antihypertensive drugs as an independent prognostic factor of OS. We identified key baseline differences in the characteristics of APC patients with and without HT, suggesting that major selection bias could occur when investigating the efficacy of antihypertensive drugs in all populations. Therefore, it is possible that antihypertensive drugs lack antitumor activity. To determine the true efficacy of antihypertensive drugs for APC, HT, and non-HT patients in another population should be investigated, or a prospective, randomized, controlled trial conducted that is stratified by HT or non-HT status.<\/jats:p>","DOI":"10.1097\/md.0000000000029532","type":"journal-article","created":{"date-parts":[[2022,7,22]],"date-time":"2022-07-22T14:05:21Z","timestamp":1658498721000},"page":"e29532","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":6,"title":["Do antihypertensive drugs really have antitumor effects? Baseline differences in hypertensive and non-hypertensive patients with advanced pancreatic cancer"],"prefix":"10.1097","volume":"101","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9366-759X","authenticated-orcid":false,"given":"Kiyotsugu","family":"Iede","sequence":"first","affiliation":[{"name":"Departments of Clinical Oncology and Higashiosaka City Medical Center, Higashiosaka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4025-6927","authenticated-orcid":false,"given":"Terumasa","family":"Yamada","sequence":"additional","affiliation":[{"name":"Gastroenterological Surgery, Higashiosaka City Medical Center, Higashiosaka, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masami","family":"Ueda","sequence":"additional","affiliation":[{"name":"Gastroenterological Surgery, Higashiosaka City Medical Center, Higashiosaka, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yujiro","family":"Tsuda","sequence":"additional","affiliation":[{"name":"Gastroenterological Surgery, Higashiosaka City Medical Center, Higashiosaka, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinsuke","family":"Nakashima","sequence":"additional","affiliation":[{"name":"Gastroenterological Surgery, Higashiosaka City Medical Center, Higashiosaka, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsuya","family":"Ohta","sequence":"additional","affiliation":[{"name":"Gastroenterological Surgery, Higashiosaka City Medical Center, Higashiosaka, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsukasa","family":"Tanida","sequence":"additional","affiliation":[{"name":"Gastroenterological Surgery, Higashiosaka City Medical Center, Higashiosaka, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin","family":"Matsuyama","sequence":"additional","affiliation":[{"name":"Gastroenterological Surgery, Higashiosaka City Medical Center, Higashiosaka, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masakazu","family":"Ikenaga","sequence":"additional","affiliation":[{"name":"Gastroenterological Surgery, Higashiosaka City Medical Center, Higashiosaka, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shusei","family":"Tominaga","sequence":"additional","affiliation":[{"name":"Departments of Clinical Oncology and Higashiosaka City Medical Center, Higashiosaka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2022,7,22]]},"reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"e63","DOI":"10.1097\/MPA.0000000000001596","article-title":"Multiple liver metastases rather than the presence of liver metastasis is a significantly poor prognostic factor for patients with advanced pancreatic cancer","volume":"49","author":"Iede","year":"2020","journal-title":"Pancreas"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1200\/JCO.1997.15.6.2403","article-title":"Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial","volume":"15","author":"Burris","year":"1997","journal-title":"J Clin Oncol"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine","volume":"369","author":"Von Hoff","year":"2013","journal-title":"N Engl J Med"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrd.2018.168","article-title":"Drug repurposing: progress, challenges and recommendations","volume":"18","author":"Pushpakom","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/s12885-022-09200-4","article-title":"Angiotensin blockade therapy and survival in pancreatic cancer: a population study","volume":"22","author":"Keith","year":"2022","journal-title":"BMC Cancer"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1097\/CAD.0000000000000947","article-title":"Calcium channel blockers in pancreatic cancer: increased overall survival in a retrospective cohort study","volume":"31","author":"Tingle","year":"2020","journal-title":"Anticancer Drugs"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1001\/jamaoncol.2019.0892","article-title":"Total neoadjuvant therapy with FOLFIRINOX in combination with losartan followed by chemoradiotherapy for locally advanced pancreatic cancer: a phase 2 clinical trial","volume":"5","author":"Murphy","year":"2019","journal-title":"JAMA Oncol"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1007\/s00432-014-1873-2","article-title":"The inhibition of renin-angiotensin system in advanced pancreatic cancer: an exploratory analysis in 349 patients","volume":"141","author":"Nakai","year":"2015","journal-title":"J Cancer Res Clin Oncol"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1007\/s10637-013-9972-5","article-title":"A multicenter phase II trial of gemcitabine and candesartan combination therapy in patients with advanced pancreatic cancer: GECA2","volume":"31","author":"Nakai","year":"2013","journal-title":"Invest New Drugs"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1111\/j.1349-7006.2012.02311.x","article-title":"Phase I trial of gemcitabine and candesartan combination therapy in normotensive patients with advanced pancreatic cancer: GECA1","volume":"103","author":"Nakai","year":"2012","journal-title":"Cancer Sci"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1038\/sj.bjc.6605955","article-title":"Inhibition of renin-angiotensin system affects prognosis of advanced pancreatic cancer receiving gemcitabine","volume":"103","author":"Nakai","year":"2010","journal-title":"Br J Cancer"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","article-title":"Toxicity and response criteria of the Eastern Cooperative Oncology Group","volume":"5","author":"Oken","year":"1982","journal-title":"Am J Clin Oncol"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.ijsu.2017.01.075","article-title":"Clinical impact of sarcopenia on prognosis in pancreatic ductal adenocarcinoma: a retrospective cohort study","volume":"39","author":"Ninomiya","year":"2017","journal-title":"Int J Surg (London, England)"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"2920","DOI":"10.1158\/1078-0432.CCR-08-2242","article-title":"Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment","volume":"15","author":"Prado","year":"2009","journal-title":"Clin Cancer Res"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1007\/s00432-009-0587-3","article-title":"Impact of angiotensin I converting enzyme inhibitors and angiotensin II type 1 receptor blockers on survival in patients with advanced non-small-cell lung cancer undergoing first-line platinum-based chemotherapy","volume":"135","author":"Wilop","year":"2009","journal-title":"J Cancer Res Clin Oncol"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1159\/000337979","article-title":"How does inhibition of the renin-angiotensin system affect the prognosis of advanced gastric cancer patients receiving platinum-based chemotherapy?","volume":"83","author":"Kim","year":"2012","journal-title":"Oncology"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1097\/MPA.0000000000001534","article-title":"FOLFIRINOX for advanced pancreatic cancer patients after Nab-paclitaxel plus gemcitabine failure","volume":"49","author":"Matsumoto","year":"2020","journal-title":"Pancreas"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"e1289","DOI":"10.1002\/cnr2.1289","article-title":"Predictive implications of decreased CA19-9 at 8 weeks during nab-paclitaxel plus gemcitabine for the induction of second-line chemotherapy for patients with advanced pancreatic cancer","volume":"3","author":"Iede","year":"2020","journal-title":"Cancer Rep (Hoboken, NJ)"},{"key":"R21-20250504","doi-asserted-by":"crossref","first-page":"e1215","DOI":"10.1002\/cnr2.1215","article-title":"Efficacy of S-1 in second-line chemotherapy after nab-paclitaxel plus gemcitabine for patients with advanced pancreatic cancer","volume":"3","author":"Iede","year":"2020","journal-title":"Cancer Rep (Hoboken, NJ)"},{"key":"R22-20250504","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S0140-6736(15)00986-1","article-title":"Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial","volume":"387","author":"Wang-Gillam","year":"2016","journal-title":"Lancet (London, England)"},{"key":"R23-20250504","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1038\/bjc.2016.185","article-title":"Second-line therapy after nab-paclitaxel plus gemcitabine or after gemcitabine for patients with metastatic pancreatic cancer","volume":"115","author":"Chiorean","year":"2016","journal-title":"Br J Cancer"},{"key":"R24-20250504","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1200\/JCO.2013.53.6995","article-title":"Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial","volume":"32","author":"Oettle","year":"2014","journal-title":"J Clin Oncol"},{"key":"R25-20250504","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1016\/j.ejca.2011.04.011","article-title":"Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group","volume":"47","author":"Pelzer","year":"2011","journal-title":"Eur J Cancer (Oxford, England: 1990)"},{"key":"R26-20250504","doi-asserted-by":"crossref","first-page":"e4","DOI":"10.1097\/MPA.0000000000001942","article-title":"Optimal relative dose intensity in the first 4 weeks during Nab-paclitaxel plus gemcitabine for older patients with advanced pancreatic cancer in Japan","volume":"51","author":"Iede","year":"2022","journal-title":"Pancreas"}],"updated-by":[{"DOI":"10.1097\/md.0000000000030451","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2022,8,26]],"date-time":"2022-08-26T00:00:00Z","timestamp":1661472000000}},{"DOI":"10.1097\/md.0000000000030450","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2022,8,26]],"date-time":"2022-08-26T00:00:00Z","timestamp":1661472000000}}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000029532","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T04:20:42Z","timestamp":1746332442000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000029532"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,22]]},"references-count":24,"journal-issue":{"issue":"29","published-online":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000029532","relation":{"correction":[{"id-type":"doi","id":"10.1097\/MD.0000000000030450","asserted-by":"object"},{"id-type":"doi","id":"10.1097\/MD.0000000000030451","asserted-by":"object"}]},"ISSN":["1536-5964"],"issn-type":[{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,22]]}}}